1
|
Loccisano AE, Bus J, Gollapudi B, Riffle B, Frericks M, Fegert I, Fabian E. Use of toxicokinetic data for afidopyropen to determine the dose levels in developmental toxicity studies. Regul Toxicol Pharmacol 2020; 113:104644. [PMID: 32194133 DOI: 10.1016/j.yrtph.2020.104644] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 02/01/2020] [Accepted: 03/13/2020] [Indexed: 11/19/2022]
Abstract
Afidopyropen is an insecticide that acts as a TRPV channel modulator in chordotonal organs of target insects and has been assessed for a wide range of toxicity endpoints including developmental toxicity in rats and rabbits. The GLP developmental toxicity study in rabbits did not produce evidence of maternal or fetal toxicity at the highest dose tested (32 mg/kg/day) but pharmacokinetics (PK) in pregnant rabbits in this study exhibited onset of PK nonlinearity from 5 mg/kg/day on, as measured by plasma Cmax and AUC. The NOAEL (32 mg/kg/day) is 9000X higher than maximum expected human dietary exposures to afidopyropen; the dose range where nonlinear PK were observed (5-15 mg/kg/day) is 1400-4200X higher. As nonlinearity occurred between 5 and 15 mg/kg/day, 32 mg/kg/day is concluded to be a sufficiently high dose (kinetically derived maximum dose) for a prenatal developmental toxicity study. As recognized by regulatory dose-selection guidance, onset of saturated PK is evidence of excessive biological stress to test animals rendering any effects at such doses of questionable relevance for human risk assessment. These data demonstrate that consideration of PK is critical for improving the dose-selection in developmental toxicity studies to enhance human relevance of animal toxicity studies.
Collapse
Affiliation(s)
| | - James Bus
- Exponent Inc, Alexandria, VA, 22314, USA
| | | | - Brandy Riffle
- BASF Corporation, Research Triangle Park, NC, 27709, USA
| | - Markus Frericks
- BASF SE Experimental Toxicology and Ecology, Ludwigshafen, Germany
| | - Ivana Fegert
- BASF SE Experimental Toxicology and Ecology, Ludwigshafen, Germany
| | - Eric Fabian
- BASF SE Experimental Toxicology and Ecology, Ludwigshafen, Germany.
| |
Collapse
|
2
|
Buelke-Sam J, Byrd RA, Hoyt JA, Zimmermann JL. A Reproductive and Developmental Toxicity Study in CD Rats of LY275585, [Lys(B28),Pro(B29)]-Human Insulin. ACTA ACUST UNITED AC 2016. [DOI: 10.3109/10915819409140597] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
LY275585, [Lys(B28),Pro(B29)]-human insulin, was administered daily by subcutaneous injection at doses of 0, 1, 5, or 20 U/kg. Male rats were treated with LY275585 beginning 2 weeks prior to cohabitation and throughout the mating period. Females assigned to the teratology component of the study were treated for 2 weeks prior to cohabitation with the males and through gestation day (GD) 19. These dams were killed on GD 20 and uterine and fetal examinations were performed. Female rats assigned to the delivery component were treated for 2 weeks prior to cohabitation through postpartum day (PD) 20. Dams were allowed to deliver and maintain their progeny through a 21-day lactation period. After weaning, 1 pup/sex/litter was assigned to the F1 generation, and these animals received no treatment. Survival, growth, behavior, and reproductive performance were evaluated, and reproductive organs were collected for histological evaluation. Treatment of F0 male and female rats with LY275585 resulted in isolated incidences of severe hypoglycemia at 5 and 20 U/kg/day and some modest changes in food consumption and body weight measures at all treatment levels. These changes were anticipated and attributed to the pharmacology of this compound. Mating and fertility of the F0 animals were unaffected by treatment. While slight decreases in fetal body weights and increased fetal runts/litter were observed in the 20-U/kg/day group, PD 1 progeny weights were not affected in the delivery component, and there was no indication of teratogenicity in this study. There were no remarkable treatment-related effects on offspring growth patterns, survival, or reproductive performance, but the F1 animals from the 20-U/kg/day treatment-derived group were more reactive than controls in the startle habituation test. Thus, F0 parental toxicity, related to the hypoglycemic action of LY275585, was found at all doses. A dose of 5 U/kg/day was considered a no-adverse-effect level for developmental toxicity. There were no remarkable effects of LY275585 treatment on F0 or F1 generation reproductive performance at 20 U/kg/day, the highest dose tested in this study.
Collapse
Affiliation(s)
- J. Buelke-Sam
- P.O. Box 708, Lilly Research Laboratories, Eli Lilly & Company, Greenfield, IN 46140, U.S.A
| | - R. A. Byrd
- P.O. Box 708, Lilly Research Laboratories, Eli Lilly & Company, Greenfield, IN 46140, U.S.A
| | - J. A. Hoyt
- P.O. Box 708, Lilly Research Laboratories, Eli Lilly & Company, Greenfield, IN 46140, U.S.A
| | - J. L. Zimmermann
- P.O. Box 708, Lilly Research Laboratories, Eli Lilly & Company, Greenfield, IN 46140, U.S.A
| |
Collapse
|
3
|
Successful pregnancy and delivery in a patient with Parkinson's disease under pramipexole treatment. Presse Med 2014; 43:83-5. [DOI: 10.1016/j.lpm.2013.01.067] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2012] [Revised: 01/03/2013] [Accepted: 01/13/2013] [Indexed: 11/15/2022] Open
|
4
|
Ha DE, Legendre G, Colau JC. Maladie de Parkinson juvénile et prématurité récidivante. À propos d'un cas. ACTA ACUST UNITED AC 2007; 35:224-7. [PMID: 17293151 DOI: 10.1016/j.gyobfe.2006.12.022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2006] [Accepted: 12/22/2006] [Indexed: 11/24/2022]
Abstract
The association of Parkinson's disease and pregnancy is very rare. Some thirty cases are found in the literature. We report the case of a pregnancy in a 30-year-old patient with juvenile Parkinson's disease. During this pregnancy treated by levodopa and bromocriptine, no aggravation of the symptoms was been observed. However, the pregnancy was complicated by a premature delivery at 31 weeks of amenorrhoea.
Collapse
Affiliation(s)
- D-E Ha
- Service de Gynécologie-Obstétrique, Hôpital Foch, 40, rue Worth, BP 36, 92151 Suresnes cedex, France.
| | | | | |
Collapse
|
5
|
Affiliation(s)
- Mark E Molitch
- Division of Endocrinology, Metabolism, and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Tarry 15-731, Chicago, IL 60611, USA.
| |
Collapse
|
6
|
Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P. Pramipexole-treated Parkinson's disease during pregnancy. Mov Disord 2004; 19:1114-5. [PMID: 15372610 DOI: 10.1002/mds.20148] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
There are few reports about drug-related effects on PD pregnancy. We describe the case of a woman affected by PD treated with pramipexole monotherapy during pregnancy. The child, born by caesarean delivery, is healthy, whereas motor disability of the mother progressively increased to the point that levodopa therapy was necessary.
Collapse
Affiliation(s)
- Marco Mucchiut
- Clinica Neurologica, Policlinico Universitario, pzza Rodolone 2, 33013 Gemona del Friuli, Udine, Italy.
| | | | | | | | | |
Collapse
|
7
|
|
8
|
Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov Disord 1998; 13:34-8. [PMID: 9452323 DOI: 10.1002/mds.870130110] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Pregnancy is rare in Parkinson's disease (PD). In the literature on studies of antiparkinsonian drugs in animals during pregnancy, there are reports on malformations of the skeletal and circulatory system. However, the majority of studies in animals have not shown any teratogenicity. Amantadine has been teratogenic in rats and selegiline has caused neurochemical and behavioral alterations in rats when coadministered with clorgyline. The published experience with humans consists of 35 pregnancies among 26 women suffering from PD, including this report, and a number of cases treated with antiparkinsonian agents for other reasons. With the exception of the majority of the cases where amantadine was used, complications have been rare. However, there are indications that suggest a possible risk of a woman's parkinsonism worsening in connection with pregnancy. We also report the case of a woman with PD who was treated with L-dopa-benserazide during an uncomplicated pregnancy and gave birth to a healthy boy without experiencing any worsening of her PD.
Collapse
Affiliation(s)
- P Hagell
- Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund, Sweden
| | | | | |
Collapse
|
9
|
Eudaly JA, Tizzano JP, Higdon GL, Todd GC. Developmental toxicity of gemcitabine, an antimetabolite oncolytic, administered during gestation to CD-1 mice. TERATOLOGY 1993; 48:365-81. [PMID: 8278936 DOI: 10.1002/tera.1420480410] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Gemcitabine was given intravenously to female mice on gestation days (GD) 6-15 at doses of 0, 0.05, 0.25, or 1.5 mg/kg/day (0, 0.15, 0.75, or 4.5 mg/m2/day, respectively). Animals assigned to the teratology segment (25/group) were killed on GD 18 for examination of maternal hematologic parameters and organ weights, as well as fetal viability, weights, and morphology. The postnatal segment females (20/group) were allowed to deliver, and offspring physical, behavioral, and reproductive parameters were monitored. After offspring weaning, these dams were killed for hematologic and organ weight evaluations. At necropsy, 3 days after the final dose, the teratology segment dams showed dose-related increases in spleen and thymus weights. These changes were accompanied by a dose-related decrease in leukocytes and modest increases in mean corpuscular volume (MCV) and hemoglobin (MCH) at the two higher doses. On postpartum day (PPD) 21, the dams in the postnatal segment showed no treatment-related effects on these organ weights or hematologic parameters, indicating recovery of these maternal parameters within 3.5 weeks following termination of treatment. The decreases in maternal body weight and food consumption observed during gestation, and in liver and uterine weights at term in the 1.5 mg/kg/day group, were considered to be secondary to a high rate of prenatal mortality, evidenced by increased resorptions in the teratology segment and decreased live litter size in both segments of the study. Additional indications of developmental toxicity in this dose group were an increased incidence of malformations, primarily cleft palate, decreased fetal weights in the teratology segment, and decreased neonatal survival in the postnatal segment.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J A Eudaly
- Toxicology Research Laboratories, Division of Eli Lilly & Company, Greenfield, Indiana 46140
| | | | | | | |
Collapse
|
10
|
Buelke-Sam J, Cohen IR, Tizzano JP, Owen NV. Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. II: Perinatal and postnatal exposure. Neurotoxicol Teratol 1991; 13:297-306. [PMID: 1886539 DOI: 10.1016/0892-0362(91)90075-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Pergolide mesylate is a dopamine agonist and, therefore, reduces prolactin secretion. In Experiment I, pregnant mice were given oral doses of 0, 0.1, 0.3, 1.0 or 3.0 mg/kg/day pergolide on GD 15 through PD 10 or 20 to identify a tolerated dose which would not markedly reduce offspring survival during late gestational and lactational exposure. Offspring survival was not affected at any dose, but dose-related decreases in progeny body weights occurred at weaning. On PD 10, suckling-induced increases in maternal serum prolactin concentrations did not occur in dams treated with 3.0 mg/kg/day. In Experiment II, pregnant mice were given oral doses of 0, 0.002, 0.1 or 3.0 mg/kg/day pergolide on GD 15 through PD 20. Dams were allowed to deliver and maintain their offspring throughout a 21-day lactation period. Growth and behavioral performance of one F1 male and one F1 female per litter were monitored, followed by a reproduction trial and terminal organ weight measurements. There were no treatment-related effects on maternal body weights, food consumption, or terminal organ weights and pathology. Three dams showed overt signs of mammary inflammation and lactational insufficiency and mean progeny survival was decreased slightly in the 3.0 mg/kg/day group. There were no adverse effects on growth, development or reproductive performance in the F1 treatment-derived generation. Neonatal negative geotaxis, 1-h activity levels at 30 and 60 days of age, auditory startle habituation at 55 days of age, and two-way active avoidance performance at 65 days of age were not affected significantly by treatment. Thus doses of pergolide that did not inhibit lactation completely in the F0 dams were found to have no enduring effects on offspring development.
Collapse
Affiliation(s)
- J Buelke-Sam
- Toxicology Research Laboratories, Eli Lilly & Company, Greenfield, IN 46140
| | | | | | | |
Collapse
|